Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Risk categories predict mRCC survival

Rini B et al. Clin Genitourin Cancer. 2018 May 3. doi: 10.1016/j.clgc.2018.04.005.

Key clinical point: The IMDC model is prognostic for responses and survival in patients with mRCC treated with sunitinib.

Major finding: Median progression-free survival for favorable, intermediate, and poor-risk patients was 14.1, 10.7, and 2.4 months, respectively.

Study details: Retrospective analysis of 375 sunitinib-treated patients in a randomized clinical trial.

Disclosures: Medical writing for the study was supported by Pfizer. Dr. Rini and his coauthors disclosed research funding and/or consulting fees from Pfizer and other companies. Four of the coauthors are Pfizer employees and stockholders.

Source: Rini B et al. Clin Genitourin Cancer. 2018 May 3. doi: 10.1016/j.clgc.2018.04.005.

Read the article.

Citation:

Rini B et al. Clin Genitourin Cancer. 2018 May 3. doi: 10.1016/j.clgc.2018.04.005.

This Week's Must Reads

Liquid biopsy aids assessment in advanced imatinib-resistant GIST, George S et al. ASCO 2018. Abstract 11511.

Rapid therapy changes fall short for metastatic GIST, Serrano-Garcia C et al. ASCO 2018, Abstract 11510.

Estimated conditional OS shows upfront TKI benefit in mRCC, Kang M et al. J Urol. 2018 June 22. doi: 10.1016/j.juro.2018.06.030

Indolent course found in rare clear cell papillary RCC , Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005

Must Reads in Renal Cell Carcinoma

Estimated conditional OS shows upfront TKI benefit in mRCC, Kang M et al. J Urol. 2018 June 22. doi: 10.1016/j.juro.2018.06.030

Indolent course found in rare clear cell papillary RCC , Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005

Study: Clear cell papillary RCC has indolent course, Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005

Some ccRCC subtypes associated with CT features, Bowen L, Xiaojing L. Acad Radiol. 2018 Jul 29. doi: 10.1016/j.acra.2018.05.002

GAG measurements offer prognostic info for RCC, Gatto F et al. Eur Urol Oncol. 2018 Jun 13. doi: 10.1016/j.euo.2018.04.015